Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
Paxman is entering a transformational growth phase, with early signs of increased system utilisation in US clinics transitioning to reimbursement. Key near-term drivers include the integration of Dignitana and accelerating recurring revenue. We believe the most important near-term events for the stock are the quarterly results and clinical updates.
Long term
6+ YEARS
With a dominant global position in scalp cooling, expanding US reimbursement and a scalable high-margin recurring revenue model, we believe Paxman is well positioned for sustained long-term growth. We also believe that the move into broader chemotherapy side-effect management with the upcoming CIPN device expands Paxman’s portfolio and addressable market, supporting margin and revenue growth beyond 2026.
Integration of Dignitana adds potential operational complexity and will, in our view, require strong execution to capture synergies.
Currency exposure to the USD may impact sales and margins in the near term due to substantial exposure to US revenues.
Relatively low barriers to entry may increase competitive pressure.
Supportive care may be among the first areas to be cut as part of cost-saving measures if those are to be realised.
Price
Fair range high value
Fair range low value
The low end of our fair value range is based on the average of our forward-looking 2026e EV/sales and forward-looking 2028e EV/EBITDA. The high end of our fair value range is based on our DCF model.
We value Paxman using a DCF model and peer multiples. We derive the low end of our fair value range using a peer-based valuation approach that applies a blend of forward-looking EV/sales and EV/EBITDA multiples. Specifically, we use 2026e EV/sales and 2028e EV/EBITDA. We believe this combination captures near-term revenue performance and medium-term earnings potential. For the high end of our fair value range, we use a DCF model, which we believe is appropriate to capture the company’s long-term earnings potential.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB